{"hands_on_practices": [{"introduction": "In modern evidence-based dermatology, clinical judgment is refined through the quantitative interpretation of diagnostic tests. This exercise provides a fundamental hands-on application of Bayes' theorem, demonstrating how a pre-test probability, based on clinical suspicion, is mathematically updated into a more definitive post-test probability using a likelihood ratio. By calculating the impact of a positive salt-split skin IIF result, you will gain a practical understanding of how a single piece of laboratory evidence can substantially shift diagnostic certainty in a case of suspected bullous pemphigoid [@problem_id:4418182].", "problem": "A 78-year-old individual with widespread tense bullae and urticarial plaques is clinically suspected to have bullous pemphigoid. The patient undergoes salt-split skin Indirect Immunofluorescence (IIF), which reveals an epidermal roof-binding pattern consistent with autoantibodies directed against hemidesmosomal antigens. Assume that, in this setting, the positive test result is associated with a positive likelihood ratio (LR; likelihood ratio) of $LR^{+}=12$. Based on epidemiologic assessment and clinical features, the pretest probability of bullous pemphigoid is estimated to be $0.60$. Starting from Bayes theorem and the definition of odds and likelihood ratios, determine the post-test probability of bullous pemphigoid after this positive salt-split IIF result. Express your final answer as a decimal fraction and round to four significant figures.", "solution": "The problem statement has been validated and is deemed sound. It presents a clear, self-contained, and scientifically grounded scenario for the application of Bayesian inference in a medical diagnostic context. All provided data—the pre-test probability, the positive likelihood ratio, and the clinical setting—are consistent and realistic. We may therefore proceed with the solution.\n\nThe problem requires the calculation of the post-test probability of a disease given a positive test result, based on the pre-test probability and the positive likelihood ratio ($LR^{+}$). The fundamental framework for this calculation is Bayes' theorem. A particularly convenient formulation of Bayes' theorem utilizes odds instead of probabilities.\n\nLet $D$ denote the event that the patient has the disease, in this case, bullous pemphigoid.\nLet $T$ denote the event that the test result is positive.\n\nThe givens are:\nThe pre-test probability of the disease, $P(D) = 0.60$.\nThe positive likelihood ratio, $LR^{+} = 12$.\n\nThe objective is to find the post-test probability of the disease given a positive test, which is denoted as $P(D|T)$.\n\nFirst, we define the \"odds\" of an event $A$ as the ratio of the probability of the event occurring to the probability of the event not occurring:\n$$\n\\text{Odds}(A) = \\frac{P(A)}{1 - P(A)}\n$$\n\nUsing this definition, we can calculate the pre-test odds of having bullous pemphigoid, $\\text{Odds}_{\\text{pre}}$:\n$$\n\\text{Odds}_{\\text{pre}} = \\frac{P(D)}{1 - P(D)} = \\frac{0.60}{1 - 0.60} = \\frac{0.60}{0.40} = 1.5\n$$\n\nThe relationship between post-test odds, pre-test odds, and the likelihood ratio is given by the odds form of Bayes' theorem:\n$$\n\\text{Odds}_{\\text{post}} = \\text{Odds}_{\\text{pre}} \\times LR\n$$\nFor a positive test result, we use the positive likelihood ratio, $LR^{+}$. Thus, the post-test odds, $\\text{Odds}_{\\text{post}}$, are:\n$$\n\\text{Odds}_{\\text{post}} = \\text{Odds}_{\\text{pre}} \\times LR^{+}\n$$\nSubstituting the given values:\n$$\n\\text{Odds}_{\\text{post}} = 1.5 \\times 12 = 18\n$$\n\nThe post-test odds represent the odds of having the disease after accounting for the positive test result. To find the post-test probability, $P(D|T)$, we must convert these odds back into a probability. The relationship between probability and odds can be inverted as follows:\nIf $\\text{Odds}(A) = O$, then $P(A) = \\frac{O}{1 + O}$.\n\nApplying this conversion to our post-test odds:\n$$\nP(D|T) = \\frac{\\text{Odds}_{\\text{post}}}{1 + \\text{Odds}_{\\text{post}}} = \\frac{18}{1 + 18} = \\frac{18}{19}\n$$\n\nFinally, we must express this fraction as a decimal and round to four significant figures as requested by the problem statement.\n$$\n\\frac{18}{19} \\approx 0.94736842...\n$$\nRounding to four significant figures gives $0.9474$.\n\nThus, the post-test probability of the patient having bullous pemphigoid after a positive salt-split skin IIF test is approximately $0.9474$.", "answer": "$$\\boxed{0.9474}$$", "id": "4418182"}, {"introduction": "Real-world diagnostics rarely involve a single, perfectly decisive test; more often, clinicians must interpret a panel of results, some of which may appear conflicting. This problem simulates such a scenario, where strong immunopathological evidence for bullous pemphigoid confronts a negative result from a key serological assay [@problem_id:4418243]. This exercise challenges you to reason from first principles, considering the diagnostic sensitivity and specificity of each test, to formulate the most accurate differential diagnosis and determine the highest-yield next steps.", "problem": "A $72$-year-old woman presents with $3$ months of intensely pruritic, tense blisters on the trunk and proximal extremities, without oral or ocular involvement. A punch biopsy shows a subepidermal blister with a prominent eosinophil-rich infiltrate. Direct immunofluorescence (DIF) of perilesional skin reveals a continuous linear deposition of immunoglobulin G and complement component $C3$ along the basement membrane zone. On $1$ molar sodium chloride salt-split skin DIF, immunoreactants localize to the epidermal roof of the split. Serum testing by enzyme-linked immunosorbent assay (ELISA) for type XVII collagen (BP180) using the non-collagenous $16$A (NC16A) domain is negative; testing for BP230 is pending. Indirect immunofluorescence (IIF) for circulating basement membrane zone antibodies has not yet been performed.\n\nUsing the fundamental principles that salt-split skin separates within the lamina lucida and that roof-binding indicates target antigens localized to hemidesmosomal/lamina lucida–associated components (for example, BP180, BP230, or integrin $\\alpha6\\beta4$), whereas floor-binding indicates dermal components (for example, type VII collagen, laminin $332$, laminin $\\gamma1$), and recognizing that a negative BP180 NC16A ELISA does not exclude bullous pemphigoid due to less than perfect sensitivity, which of the following is the most accurate interpretation of these findings and the highest-yield next diagnostic steps to refine the differential diagnosis?\n\nA. The pattern argues strongly for epidermolysis bullosa acquisita; order type VII collagen serology and expect dermal-side (floor) binding on split skin.\n\nB. The pattern is compatible with bullous pemphigoid despite a negative BP180 NC16A ELISA and also with linear immunoglobulin A bullous dermatosis and anti-integrin $\\alpha6\\beta4$ mucous membrane pemphigoid; prioritize anti-BP230 ELISA, immunoblot for LAD-$1$ (the $120$-kilodalton ectodomain of BP180), and clinical assessment for mucosal disease.\n\nC. The findings rule out bullous pemphigoid and favor anti-laminin $332$ mucous membrane pemphigoid; malignancy screening is the key next step.\n\nD. The roof-binding is pathognomonic for linear immunoglobulin A bullous dermatosis; no further testing is needed.\n\nE. The results indicate paraneoplastic pemphigus; perform IIF on rat bladder epithelium for anti-plakin antibodies as the primary next test.", "solution": "The scenario requires integration of two well-tested pillars: the salt-split skin principle and the test characteristics of enzyme-linked immunosorbent assay (ELISA) for type XVII collagen (BP180). First, the salt-split technique cleaves within the lamina lucida; binding to the epidermal roof indicates that the target antigen is located within or above the lamina lucida in hemidesmosomal structures of basal keratinocytes, such as BP180 (type XVII collagen), BP230, and integrin $\\alpha6\\beta4$. Conversely, dermal floor binding indicates antigens below the lamina lucida, such as type VII collagen (anchoring fibrils), laminin $332$ (formerly laminin $5$), or laminin $\\gamma1$ (the so-called p$200$ antigen). Second, the sensitivity of BP180 NC16A ELISA for bullous pemphigoid is high but not perfect (approximately $80$–$90\\%$), so a negative result does not exclude bullous pemphigoid. Moreover, not all roof-binding entities are BP180 NC16A–positive: linear immunoglobulin A bullous dermatosis commonly targets LAD-$1$ (the $120$-kilodalton ectodomain of BP180) and may be negative on NC16A-specific ELISAs, and mucous membrane pemphigoid due to anti-integrin $\\alpha6\\beta4$ can also yield roof binding.\n\nApplying these principles:\n\n- Roof-binding on salt-split DIF strongly argues against dermal floor antigen diseases such as epidermolysis bullosa acquisita (type VII collagen), anti-laminin $332$ mucous membrane pemphigoid, and anti-laminin $\\gamma1$ (p$200$) pemphigoid, all of which typically show floor binding. Thus, those are deprioritized in the differential, given the presented pattern.\n- Despite a negative BP180 NC16A ELISA, bullous pemphigoid remains plausible because ELISA sensitivity is less than $100\\%$, some patients are BP230-predominant, and some have reactivity to BP180 epitopes outside NC16A or to the shed ectodomain LAD-$1$ not captured by NC16A kits.\n- Linear immunoglobulin A bullous dermatosis is also compatible with roof binding and frequently targets LAD-$1$, supporting immunoblotting for LAD-$1$ and checking for linear IgA on IIF.\n- Anti-integrin $\\alpha6\\beta4$ mucous membrane pemphigoid, which often has predominant mucosal disease, is another roof-binding entity; correlating with mucosal involvement and specialized immunoassays is appropriate.\n\nTherefore, the next steps that best refine the differential include anti-BP230 ELISA (to detect BP230-predominant bullous pemphigoid), immunoblotting for LAD-$1$ (to evaluate linear immunoglobulin A bullous dermatosis and some bullous pemphigoid sera), and targeted assessment for mucosal disease with reflex testing for anti-integrin $\\alpha6\\beta4$ if indicated. Indirect immunofluorescence on salt-split skin for isotype characterization (immunoglobulin G versus immunoglobulin A) can further differentiate bullous pemphigoid from linear immunoglobulin A bullous dermatosis.\n\nOption-by-option analysis:\n\nA. Incorrect. Epidermolysis bullosa acquisita targets type VII collagen in anchoring fibrils and classically yields dermal floor binding on salt-split skin. The observed epidermal roof binding argues against epidermolysis bullosa acquisita, so ordering type VII collagen serology based on this pattern is not the highest-yield next step.\n\nB. Correct. Roof binding focuses the differential on antigens localized to hemidesmosomal/lamina lucida structures (BP180, BP230, integrin $\\alpha6\\beta4$). A negative BP180 NC16A ELISA does not exclude bullous pemphigoid (sensitivity approximately $80$–$90\\%$) and also does not exclude linear immunoglobulin A bullous dermatosis targeting LAD-$1$. Appropriate next tests include anti-BP230 ELISA, immunoblot for LAD-$1$, consideration of mucosal disease, and, if indicated, assays for anti-integrin $\\alpha6\\beta4$.\n\nC. Incorrect. Anti-laminin $332$ mucous membrane pemphigoid typically shows dermal floor binding on salt-split skin, the opposite of the observed epidermal roof binding. Although malignancy screening is relevant once anti-laminin $332$ is established, the current pattern does not support this diagnosis.\n\nD. Incorrect. Roof binding is not pathognomonic for linear immunoglobulin A bullous dermatosis; bullous pemphigoid and anti-integrin $\\alpha6\\beta4$ mucous membrane pemphigoid also commonly yield roof binding. Additional testing is needed to differentiate these entities.\n\nE. Incorrect. Paraneoplastic pemphigus typically shows intercellular staining (desmoglein and plakin family antigens) and a lichenoid/interface dermatitis histopathology; when basement membrane zone staining occurs, it is not characteristically isolated roof binding on salt-split skin. The presented pattern and clinicopathology do not primarily indicate paraneoplastic pemphigus, making IIF on rat bladder epithelium a lower-yield next step compared with tests targeting roof-binding pemphigoid antigens.", "answer": "$$\\boxed{B}$$", "id": "4418243"}, {"introduction": "Moving beyond single test interpretation, this advanced practice places you in the role of designing and applying a comprehensive diagnostic algorithm for ambiguous cases. You are presented with multiple test results for several patients, each with a specific likelihood ratio ($LR$) that quantifies its evidentiary weight [@problem_id:4418247]. By systematically combining these likelihood ratios through Bayesian updating, you will learn to integrate a complete set of immunopathological data into a single, coherent posterior probability, allowing for a rigorous, data-driven classification of challenging subepidermal blistering diseases.", "problem": "An elderly cohort presents with subepidermal blistering disease where clinical features are insufficient to discriminate bullous pemphigoid from other immunobullous disorders. You are asked to choose a decision algorithm for interpreting Indirect Immunofluorescence (IIF), the salt-split skin technique, and Enzyme-Linked Immunosorbent Assay (ELISA) results in ambiguous cases. The chosen algorithm must be justified by first principles: immunopathological target localization and probabilistic inference via Bayes theorem. Definitions: In bullous pemphigoid, Immunoglobulin G (IgG) autoantibodies target hemidesmosomal antigens Bullous Pemphigoid antigen 180 (BP180; also called collagen XVII) and Bullous Pemphigoid antigen 230 (BP230); on salt-split human skin, binding predominantly to the epidermal roof supports bullous pemphigoid, whereas binding to the dermal floor supports diseases such as Epidermolysis Bullosa Acquisita (EBA; anti-type VII collagen) or anti-laminin 332 Mucous Membrane Pemphigoid (MMP). Basement Membrane Zone (BMZ) IIF titers reflect circulating anti-BMZ antibodies. ELISA for BP180 NC16A and BP230 measures antigen-specific IgG.\n\nAssume the following test characteristics are well-validated and independent enough for approximate multiplicative updating of odds. Likelihood ratios for bullous pemphigoid ($LR_{\\text{BP}}$) given observations are:\n- Salt-split roof-exclusive binding: $LR_{\\text{BP}} = 20$.\n- Salt-split mixed (roof-predominant with faint floor): $LR_{\\text{BP}} = 5$.\n- Salt-split floor-exclusive binding: $LR_{\\text{BP}} = 0.05$.\n- ELISA BP180 NC16A positive ($\\ge 20$ units): $LR_{\\text{BP}} = 16$; negative: $LR_{\\text{BP}} = 0.21$.\n- ELISA BP230 positive ($\\ge 20$ units): $LR_{\\text{BP}} = 5$; negative: $LR_{\\text{BP}} = 0.7$.\n- IIF BMZ titer $\\ge 1\\!:\\!160$: $LR_{\\text{BP}} = 6$; IIF $\\ge 1\\!:\\!40$ but $< 1\\!:\\!160$: $LR_{\\text{BP}} = 2$; IIF negative: $LR_{\\text{BP}} = 0.7$.\n\nUse posterior probability thresholds: classify as bullous pemphigoid if $P(\\text{BP}|\\text{data}) \\ge 0.85$, classify as non-bullous pemphigoid (favoring EBA or anti-laminin 332 MMP) if $P(\\text{BP}|\\text{data}) \\le 0.15$, otherwise indeterminate. The pretest probability is estimated from clinical features as follows:\n- Patient $X$: $P_0 = 0.50$. IIF BMZ $1\\!:\\!40$; salt-split mixed (roof-predominant with faint floor); ELISA BP180 $18$ units (negative), ELISA BP230 $45$ units (positive).\n- Patient $Y$: $P_0 = 0.40$. IIF BMZ negative; salt-split floor-exclusive binding; ELISA BP180 $35$ units (positive), ELISA BP230 $5$ units (negative).\n- Patient $Z$: $P_0 = 0.60$. IIF BMZ $1\\!:\\!160$; salt-split roof-exclusive binding; ELISA BP180 $10$ units (negative), ELISA BP230 $8$ units (negative).\n\nWhich of the following algorithms most appropriately integrates immunopathological localization with probabilistic inference to produce correct classifications for $X$, $Y$, and $Z$ under the stated thresholds?\n\nA. Classify bullous pemphigoid if any single test is positive (IIF titer $\\ge 1\\!:\\!40$, roof-binding on salt-split, or either ELISA positive); classify non-bullous pemphigoid if salt-split shows floor-exclusive binding or if all tests are negative; do not combine results across tests.\n\nB. Apply stepwise Bayesian updating beginning with the salt-split result (highest discriminatory localization), then ELISA BP180, then ELISA BP230, then IIF titer, multiplying $LR_{\\text{BP}}$ at each step into the prior odds $P_0/(1-P_0)$ until the posterior probability crosses $0.85$ (bullous pemphigoid) or $0.15$ (non-bullous pemphigoid); if neither threshold is reached after all tests, label indeterminate.\n\nC. Combine all available tests simultaneously by multiplying all $LR_{\\text{BP}}$ into prior odds, but use a classification threshold of $P(\\text{BP}|\\text{data}) \\ge 0.50$ for bullous pemphigoid; otherwise non-bullous pemphigoid.\n\nD. Use a points-based score: roof-exclusive binding $= +3$, mixed binding $= +1$, BP180 positive $= +2$, BP230 positive $= +1$, IIF $\\ge 1\\!:\\!160$ $= +1$; classify bullous pemphigoid if total $\\ge 3$, otherwise non-bullous pemphigoid; do not calculate probabilities.\n\nE. Prioritize ELISA: if BP180 is positive, classify bullous pemphigoid regardless of salt-split; if BP180 is negative but BP230 is positive, still classify bullous pemphigoid; if both are negative, classify non-bullous pemphigoid; ignore IIF and salt-split findings to avoid conflicting signals.", "solution": "### Problem Validation\n\nThe problem statement is a well-defined exercise in medical decision-making, using probabilistic reasoning. I will proceed with a formal validation.\n\n**Step 1: Extract Givens**\n\n*   **Disease of Interest:** Bullous Pemphigoid (BP).\n*   **Pathophysiology:** IgG autoantibodies target hemidesmosomal antigens BP180 and BP230. On salt-split skin, this results in binding to the epidermal roof.\n*   **Differential Diagnoses:** Epidermolysis Bullosa Acquisita (EBA, anti-type VII collagen), anti-laminin 332 Mucous Membrane Pemphigoid (MMP). These show binding to the dermal floor on salt-split skin.\n*   **Tests:** Indirect Immunofluorescence (IIF) for Basement Membrane Zone (BMZ) antibodies, salt-split skin technique, and Enzyme-Linked Immunosorbent Assay (ELISA) for BP180 NC16A and BP230.\n*   **Assumption:** Test results are sufficiently independent for multiplicative updating of odds using their likelihood ratios.\n*   **Likelihood Ratios for Bullous Pemphigoid ($LR_{\\text{BP}}$):**\n    *   Salt-split roof-exclusive binding: $LR_{\\text{BP}} = 20$.\n    *   Salt-split mixed (roof-predominant, faint floor): $LR_{\\text{BP}} = 5$.\n    *   Salt-split floor-exclusive binding: $LR_{\\text{BP}} = 0.05$.\n    *   ELISA BP180 positive ($\\ge 20$ units): $LR_{\\text{BP}} = 16$.\n    *   ELISA BP180 negative ($< 20$ units): $LR_{\\text{BP}} = 0.21$.\n    *   ELISA BP230 positive ($\\ge 20$ units): $LR_{\\text{BP}} = 5$.\n    *   ELISA BP230 negative ($< 20$ units): $LR_{\\text{BP}} = 0.7$.\n    *   IIF BMZ titer $\\ge 1\\!:\\!160$: $LR_{\\text{BP}} = 6$.\n    *   IIF BMZ titer $\\ge 1\\!:\\!40$ but $< 1\\!:\\!160$: $LR_{\\text{BP}} = 2$.\n    *   IIF BMZ negative: $LR_{\\text{BP}} = 0.7$.\n*   **Classification Thresholds:**\n    *   Classify as BP if $P(\\text{BP}|\\text{data}) \\ge 0.85$.\n    *   Classify as non-BP if $P(\\text{BP}|\\text{data}) \\le 0.15$.\n    *   Classify as Indeterminate if $0.15 < P(\\text{BP}|\\text{data}) < 0.85$.\n*   **Patient Data:**\n    *   **Patient X:** Pre-test probability $P_0 = 0.50$. IIF BMZ $1\\!:\\!40$; salt-split mixed; ELISA BP180 $18$ units (negative); ELISA BP230 $45$ units (positive).\n    *   **Patient Y:** Pre-test probability $P_0 = 0.40$. IIF BMZ negative; salt-split floor-exclusive; ELISA BP180 $35$ units (positive); ELISA BP230 $5$ units (negative).\n    *   **Patient Z:** Pre-test probability $P_0 = 0.60$. IIF BMZ $1\\!:\\!160$; salt-split roof-exclusive; ELISA BP180 $10$ units (negative); ELISA BP230 $8$ units (negative).\n\n**Step 2: Validate Using Extracted Givens**\n\n*   **Scientifically Grounded:** The problem is firmly rooted in the immunopathology of bullous diseases and the standard diagnostic application of Bayesian inference. The tests, antigens, and interpretation principles are all standard in dermatology and laboratory medicine. The likelihood ratio values are plausible for such diagnostic tests.\n*   **Well-Posed:** The problem is well-posed. It provides all necessary components: prior probabilities, a complete set of test results for three distinct cases, a full list of likelihood ratios corresponding to all possible test outcomes, and explicit, unambiguous classification thresholds. The objective is clearly stated.\n*   **Objective:** The problem is stated in objective, quantitative terms, free from bias or subjective language.\n\n**Step 3: Verdict and Action**\n\nThe problem statement is scientifically sound, complete, and well-posed. It is a valid exercise in applying first principles of probabilistic diagnosis. I will proceed to the solution.\n\n### Derivation of Correct Classifications\n\nThe problem requires the application of Bayes' theorem in odds form. The posterior odds of having BP are calculated by multiplying the prior odds by the likelihood ratios of all observed test results.\n\nThe key equations are:\n1.  Prior Odds: $O_{\\text{prior}} = \\frac{P_0}{1 - P_0}$\n2.  Posterior Odds: $O_{\\text{post}} = O_{\\text{prior}} \\times \\prod_{i} LR_i$\n3.  Posterior Probability: $P_{\\text{post}} = \\frac{O_{\\text{post}}}{1 + O_{\\text{post}}}$\n\nI will now calculate the posterior probability for each patient.\n\n**Patient X:**\n*   Prior Probability: $P_0 = 0.50$.\n*   Prior Odds: $O_{\\text{prior}} = \\frac{0.50}{1 - 0.50} = 1.0$.\n*   Test Results and corresponding $LR_{\\text{BP}}$:\n    *   IIF BMZ $1\\!:\\!40$: $LR_1 = 2$.\n    *   Salt-split mixed: $LR_2 = 5$.\n    *   ELISA BP180 negative: $LR_3 = 0.21$.\n    *   ELISA BP230 positive: $LR_4 = 5$.\n*   Calculation:\n    *   $O_{\\text{post}} = O_{\\text{prior}} \\times LR_1 \\times LR_2 \\times LR_3 \\times LR_4 = 1.0 \\times 2 \\times 5 \\times 0.21 \\times 5 = 10.5$.\n    *   $P_{\\text{post}} = \\frac{10.5}{1 + 10.5} = \\frac{10.5}{11.5} \\approx 0.913$.\n*   Classification: Since $0.913 \\ge 0.85$, Patient X is classified as **Bullous Pemphigoid (BP)**.\n\n**Patient Y:**\n*   Prior Probability: $P_0 = 0.40$.\n*   Prior Odds: $O_{\\text{prior}} = \\frac{0.40}{1 - 0.40} = \\frac{0.4}{0.6} = \\frac{2}{3}$.\n*   Test Results and corresponding $LR_{\\text{BP}}$:\n    *   IIF BMZ negative: $LR_1 = 0.7$.\n    *   Salt-split floor-exclusive: $LR_2 = 0.05$.\n    *   ELISA BP180 positive: $LR_3 = 16$.\n    *   ELISA BP230 negative: $LR_4 = 0.7$.\n*   Calculation:\n    *   $O_{\\text{post}} = O_{\\text{prior}} \\times LR_1 \\times LR_2 \\times LR_3 \\times LR_4 = \\frac{2}{3} \\times 0.7 \\times 0.05 \\times 16 \\times 0.7$.\n    *   $O_{\\text{post}} = \\frac{2}{3} \\times (0.7 \\times 0.7) \\times (0.05 \\times 16) = \\frac{2}{3} \\times 0.49 \\times 0.8 = \\frac{2}{3} \\times 0.392 \\approx 0.2613$.\n    *   $P_{\\text{post}} = \\frac{0.2613}{1 + 0.2613} = \\frac{0.2613}{1.2613} \\approx 0.207$.\n*   Classification: Since $0.15 < 0.207 < 0.85$, Patient Y is classified as **Indeterminate**.\n\n**Patient Z:**\n*   Prior Probability: $P_0 = 0.60$.\n*   Prior Odds: $O_{\\text{prior}} = \\frac{0.60}{1 - 0.60} = \\frac{0.6}{0.4} = 1.5$.\n*   Test Results and corresponding $LR_{\\text{BP}}$:\n    *   IIF BMZ $\\ge 1\\!:\\!160$: $LR_1 = 6$.\n    *   Salt-split roof-exclusive: $LR_2 = 20$.\n    *   ELISA BP180 negative: $LR_3 = 0.21$.\n    *   ELISA BP230 negative: $LR_4 = 0.7$.\n*   Calculation:\n    *   $O_{\\text{post}} = O_{\\text{prior}} \\times LR_1 \\times LR_2 \\times LR_3 \\times LR_4 = 1.5 \\times 6 \\times 20 \\times 0.21 \\times 0.7$.\n    *   $O_{\\text{post}} = 1.5 \\times 120 \\times 0.147 = 180 \\times 0.147 = 26.46$.\n    *   $P_{\\text{post}} = \\frac{26.46}{1 + 26.46} = \\frac{26.46}{27.46} \\approx 0.964$.\n*   Classification: Since $0.964 \\ge 0.85$, Patient Z is classified as **Bullous Pemphigoid (BP)**.\n\n**Summary of Correct Classifications:**\n*   Patient X: **BP**\n*   Patient Y: **Indeterminate**\n*   Patient Z: **BP**\n\n### Option-by-Option Analysis\n\nNow I will evaluate each proposed algorithm against these derived classifications and the problem's first principles.\n\n**A. Classify bullous pemphigoid if any single test is positive (IIF titer $\\ge 1\\!:\\!40$, roof-binding on salt-split, or either ELISA positive); classify non-bullous pemphigoid if salt-split shows floor-exclusive binding or if all tests are negative; do not combine results across tests.**\nThis algorithm is a simplistic, non-probabilistic heuristic. It ignores the principle of integrating evidence by using a disjunctive \"any positive\" rule and has potential for internal contradiction.\n*   Patient X: Positive on IIF ($1\\!:\\!40$), salt-split (mixed, a form of roof binding), and BP230 ELISA. Classified as BP. (Correct classification, flawed method).\n*   Patient Y: Positive on BP180 ELISA (classifies as BP) but also has floor-exclusive salt-split binding (classifies as non-BP). The algorithm is contradictory and fails to provide a single classification.\n*   Patient Z: Positive on IIF ($\\ge 1\\!:\\!160$) and salt-split (roof-exclusive). Classified as BP. (Correct classification, flawed method).\nThis algorithm fails on principle by not integrating evidence and in practice by being contradictory for Patient Y.\n**Verdict: Incorrect.**\n\n**B. Apply stepwise Bayesian updating beginning with the salt-split result (highest discriminatory localization), then ELISA BP180, then ELISA BP230, then IIF titer, multiplying $LR_{\\text{BP}}$ at each step into the prior odds $P_0/(1-P_0)$ until the posterior probability crosses $0.85$ (bullous pemphigoid) or $0.15$ (non-bullous pemphigoid); if neither threshold is reached after all tests, label indeterminate.**\nThis algorithm correctly describes the process of Bayesian updating. It uses the prior odds, multiplies all relevant likelihood ratios, and applies the specified classification thresholds. The \"stepwise\" nature and the order of test application are immaterial to the final result, as multiplication is commutative. This algorithm faithfully implements the principles required by the problem statement.\n*   Patient X: Calculation yields $P_{\\text{post}} \\approx 0.913$, which is $\\ge 0.85$. Classification is BP. Correct.\n*   Patient Y: Calculation yields $P_{\\text{post}} \\approx 0.207$, which is between $0.15$ and $0.85$. Classification is Indeterminate. Correct.\n*   Patient Z: Calculation yields $P_{\\text{post}} \\approx 0.964$, which is $\\ge 0.85$. Classification is BP. Correct.\nThis algorithm correctly describes the required methodology and leads to the correct classification for all three patients.\n**Verdict: Correct.**\n\n**C. Combine all available tests simultaneously by multiplying all $LR_{\\text{BP}}$ into prior odds, but use a classification threshold of $P(\\text{BP}|\\text{data}) \\ge 0.50$ for bullous pemphigoid; otherwise non-bullous pemphigoid.**\nThis algorithm correctly combines the evidence using LRs, but it violates the problem's stated classification rules. It uses an incorrect threshold ($0.50$) and eliminates the \"Indeterminate\" category.\n*   Patient X: $P_{\\text{post}} \\approx 0.913 \\ge 0.50$. Classified as BP. (Correct classification, wrong threshold).\n*   Patient Y: $P_{\\text{post}} \\approx 0.207 < 0.50$. Classified as non-BP. This is an incorrect classification; the result should be Indeterminate.\n*   Patient Z: $P_{\\text{post}} \\approx 0.964 \\ge 0.50$. Classified as BP. (Correct classification, wrong threshold).\nBecause this algorithm misclassifies Patient Y and uses thresholds that contradict the problem setup, it is incorrect.\n**Verdict: Incorrect.**\n\n**D. Use a points-based score: roof-exclusive binding $= +3$, mixed binding $= +1$, BP180 positive $= +2$, BP230 positive $= +1$, IIF $\\ge 1\\!:\\!160$ $= +1$; classify bullous pemphigoid if total $\\ge 3$, otherwise non-bullous pemphigoid; do not calculate probabilities.**\nThis algorithm replaces rigorous Bayesian updating with a simplified, arbitrary scoring system. It does not use prior probabilities and does not properly weigh negative results or lower-level positive results. This violates the problem's directive to use probabilistic inference.\n*   Patient X: Mixed binding ($+1$) + BP230 positive ($+1$) = Total score of $2$. Since $2 < 3$, this algorithm classifies as non-BP. This is incorrect.\n*   Patient Y: BP180 positive ($+2$) = Total score of $2$. Since $2 < 3$, this algorithm classifies as non-BP. This is incorrect.\n*   Patient Z: Roof-exclusive binding ($+3$) + IIF $\\ge 1\\!:\\!160$ ($+1$) = Total score of $4$. Since $4 \\ge 3$, this algorithm classifies as BP. This is correct.\nThe algorithm fails for two out of three patients.\n**Verdict: Incorrect.**\n\n**E. Prioritize ELISA: if BP180 is positive, classify bullous pemphigoid regardless of salt-split; if BP180 is negative but BP230 is positive, still classify bullous pemphigoid; if both are negative, classify non-bullous pemphigoid; ignore IIF and salt-split findings to avoid conflicting signals.**\nThis algorithm is a flawed hierarchical model that explicitly ignores evidence, which is the antithesis of the Bayesian approach. It discards valuable information, particularly from salt-split skin, which has the most extreme LRs ($20$ and $0.05$).\n*   Patient X: BP180 negative, BP230 positive. Classified as BP. (Correct classification, flawed method).\n*   Patient Y: BP180 positive. Classified as BP. This is incorrect; the correct classification is Indeterminate. The algorithm ignores the very strong evidence against BP from the salt-split result ($LR = 0.05$).\n*   Patient Z: Both ELISAs are negative. Classified as non-BP. This is incorrect; the correct classification is BP. The algorithm ignores the very strong evidence for BP from the salt-split ($LR = 20$) and IIF ($LR = 6$) results.\nThis algorithm fails for two of the three patients.\n**Verdict: Incorrect.**", "answer": "$$\\boxed{B}$$", "id": "4418247"}]}